story of the week
Rindopepimut With Bevacizumab for Patients With Relapsed EGFRvIII-Expressing Glioblastoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Rindopepimut With Bevacizumab for Patients With Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial
Clin. Cancer Res 2020 Feb 07;[EPub Ahead of Print], DA Reardon, A Desjardins, JJ Vredenburgh, DM O'Rourke, DD Tran, KL Fink, LB Nabors, G Li, DA Bota, RV Lukas, LS Ashby, JP Duic, MM Mrugala, S Cruickshank, L Vitale, Y He, JA Green, MJ Yellin, CD Turner, T Keler, TA Davis, JH SampsonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.